view more

Targeting Aβ and Tau Together A Breakthrough in Alzheimer's Treatment

Targeting Aβ and Tau Together A Breakthrough in Alzheimer's Treatment

With innovation and research, L&J BIO is pioneering a new paradigm in neuroscience.

뇌혈관 사진 뇌혈관 사진 모바일버전

Dual Action
Therapy(DAT) Platform

We are developing a dual-action therapy that targets both amyloid-beta and phosphorylated tau – the two key causes of Alzheimer's Disease. By addressing these pathologies simultaneously, our Dual Action Therapy Platform aims to go beyond slowing symptoms – and instead, alter the course of the disease itself. Grounded in rigorous science and guided by compassion, our approach reflects a singular mission: to bring lasting hope to patients, families, and future generations.

VIEW MORE

AL04 : A Breakthrough in Molecular Design

AL04 is a recombinant fusion protein engineered to cross the blood-brain barrier and act directly within the brain tissue. By overcoming one of the greatest challenges in neurodegenerative diseases such as Alzheimer’s and Parkinson’s. It represents a new frontier in the design of brain-penetrant biologics.

VIEW MORE

USPTO Patent Issued

We are proud to announce the granting of our latest U.S. patent – a key milestone that reinforces our leadership in Alzheimer’s innovation. This achievement strengthens the foundation of our technology and affirms the originality of our approach. With this patent, L&J BIO continues to advance its position at the forefront of developing transformative therapies for neurological disease.

VIEW MORE

MERIT

Protecting Memories,
Opening New Horizons

Reliable drug development through a global network
Supported by leading research institutions, a distinguished scientific advisory board, and industry veterans with IPO and FDA experience, we’ve built a strong global network to guide every step of our development process.
The DAT Platform : Groundbreaking the Future of Treatment
Our Dual Action Therapy (DAT) Platform demonstrates the effectiveness of simultaneously targeting amyloid-beta and phosphorylated tau. By addressing both pathologies, the DAT Platform is redefining the boundaries of what’s possible in neurodegenerative treatment.
Driving breakthroughs in Alzheimer's care
L&J BIO is focused on addressing the root causes of AD and developing targeted treatments for neurodegenerative disorders – offering renewed hope for patients and families affected by aging-related conditions.
scroll